Reprogrammed Interchange Llc Sells 27,624 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Key Points

• Reprogrammed Interchange LLC, a major shareholder of Vor Biopharma, sold 27,624 shares at an average price of $33.84, totaling approximately $934,796.16, reducing their holdings by 1.81% to 1,498,921 shares.
• Vor Biopharma's stock decreased by 1.2% to $33.40 during trading, with key metrics indicating a market cap of $228.79 million and a P/E ratio of -0.12.
• The company recently reported a quarterly loss of ($43.60) EPS, which missed analysts' consensus estimates by a significant margin of ($32.20).

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 27,624 shares of the stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $33.84, for a total transaction of $934,796.16. Following the completion of the transaction, the insider directly owned 1,498,921 shares of the company's stock, valued at approximately $50,723,486.64. The trade was a 1.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Monday, October 6th, Reprogrammed Interchange Llc sold 70,763 shares of Vor Biopharma stock. The shares were sold at an average price of $37.01, for a total transaction of $2,618,938.63.
• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The stock was sold at an average price of $37.83, for a total transaction of $298,894.83.
• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The stock was sold at an average price of $39.83, for a total transaction of $1,292,523.33.
• On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The stock was sold at an average price of $39.19, for a total transaction of $54,866.00.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The shares were sold at an average price of $1.54, for a total transaction of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The shares were sold at an average price of $30.80, for a total transaction of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The shares were sold at an average price of $32.80, for a total transaction of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The shares were sold at an average price of $35.00, for a total transaction of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 14,240 shares of Vor Biopharma stock. The shares were sold at an average price of $36.60, for a total transaction of $521,184.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The stock was sold at an average price of $39.80, for a total transaction of $924,195.80.

Vor Biopharma Stock Down 1.2%

NASDAQ:VOR traded down $0.40 during trading hours on Wednesday, reaching $33.40. The company's stock had a trading volume of 436,485 shares, compared to its average volume of 391,343. The stock has a market cap of $228.79 million, a P/E ratio of -0.12 and a beta of 2.07. Vor Biopharma Inc. has a 12 month low of $2.62 and a 12 month high of $65.80. The firm has a 50 day simple moving average of $38.36.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Institutional Investors Weigh In On Vor Biopharma

Large investors have recently made changes to their positions in the stock. Money Concepts Capital Corp grew its holdings in shares of Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after buying an additional 26,535 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after buying an additional 58,247 shares during the last quarter. XTX Topco Ltd purchased a new stake in Vor Biopharma in the second quarter valued at $66,000. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma in the first quarter valued at $100,000. Finally, Jane Street Group LLC purchased a new stake in Vor Biopharma in the first quarter valued at $140,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on VOR shares. HC Wainwright reissued a "buy" rating and issued a $60.00 price objective on shares of Vor Biopharma in a research note on Thursday, August 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vor Biopharma in a report on Wednesday. Wedbush reaffirmed an "outperform" rating on shares of Vor Biopharma in a report on Thursday, June 26th. Wall Street Zen lowered shares of Vor Biopharma to a "strong sell" rating in a report on Saturday, June 28th. Finally, Stifel Nicolaus raised shares of Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 price target on the stock in a report on Wednesday, September 24th. Five equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $113.83.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.